The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
30
Solution for Subcutaneous Injection.
Solution for Subcutaneous Injection.
Percent change in Total Immunoglobulin G (IgG)
Time frame: Baseline and At Week 12
Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Baseline Up to Week 116
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tri Valley Neurology Medical Associates Inc.
Mission Hills, California, United States
RECRUITINGNeurology Offices
Boca Raton, Florida, United States
RECRUITINGSFM Clinical Reseach, LLC
Boca Raton, Florida, United States
RECRUITINGHomestead Associates in Research
Homestead, Florida, United States
RECRUITINGUF Health Jacksonville Respiratory Therapy (PFT and DLCO)
Jacksonville, Florida, United States
RECRUITINGY & L Advance Health Care, Inc D/B/A Elite Clinical Research - Neurology
Miami, Florida, United States
RECRUITINGQuantix Research
Miami, Florida, United States
RECRUITINGHawaii Pacific Neuroscience
Honolulu, Hawaii, United States
RECRUITINGHSHS Medical Group - St. Elizabeth's Hospital
O'Fallon, Illinois, United States
RECRUITINGLas Vegas Neurology Center
Las Vegas, Nevada, United States
RECRUITING...and 18 more locations